Study Links Fat Transport Molecules to Alzheimer’s Risk Based on Genetics
Research finds lysophosphatidylcholines either promote or protect against disease depending on APOE ε4 gene status, with implications for personalized treatments.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Study Demonstrates Accuracy of Two Quest Blood Tests for Alzheimer’s Diagnosis
Two biomarker panels demonstrated 91% sensitivity and specificity in symptomatic patients, potentially reducing the need for PET imaging confirmation.
Dementias & Alzheimer’s
Latest
Korean Researchers Develop SERS Platform 100,000 Times More Sensitive Than ELISA for Alzheimer’s Detection
The surface-enhanced Raman spectroscopy platform can detect amyloid beta biomarkers at ultra-low concentrations in body fluids, potentially enabling earlier diagnosis and monitoring of disease progression.
Are AI-Powered Neurodiagnostic Solutions the New Frontier in Alzheimer’s Prevention?
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
Read More
Quest Diagnostics to Offer Fujirebio Blood Test for Alzheimer’s
Quest Diagnostics will offer a Fujirebio blood test this summer to enhance early detection of Alzheimer’s disease.
Read More
Simoa Technology Platform Expands Into New Market
Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration in South Korea.
Read More
Blood Test for Alzheimer’s Cleared by FDA
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
Read More
Test Detects P-SYN in Skin Biopsies of Patients with iRBD
Summary: CND Life Sciences has released baseline results from its NIH-funded Syn-Sleep Study,...
Read More
NULISAseq CNS Disease Panel 120 Expanded with Blood-Based Brain-Derived pTau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read More
Astrocytes Play Key Role in Alzheimer’s Disease
Researchers have identified the key enzyme causing Alzheimer’s disease by linking it to excessive GABA production in reactive astrocytes.
Read More
Blood Test Provides Accurate Results for Alzheimer’s Detection
A large international study found that a simpler blood test method using plasma P-tau217 can accurately detect Alzheimer’s disease.
Read More
Parkinson’s Disease Needs Improved Diagnostic Processes
A study found that up to 17.7% of initial Parkinson’s disease diagnoses are later revised, highlighting the challenges of its diagnosis.
Read More
Blood-Based Biomarker Test Accelerates Path to Diagnosis of Alzheimer’s Disease
Labcorp has launched a nationwide blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, to aid in diagnosing Alzheimer’s disease.
Read More
pTau217 Antibody Demonstrates High Rate of Reliability and Scalability
ALZpath, Inc. announced that it presented data from evaluations of its proprietary pTau217 antibody for blood-based Alzheimer’s diagnostics.
Read More
Alzheimer’s Disease Diagnosed with Highly Accurate Blood Test
A new blood test for Alzheimer’s disease not only aids in diagnosis but also helps determine the disease’s progression.
Read More
Video Game Test May Be as Effective as Blood Tests for Alzheimer’s Early Detection
A video game test may help detect Alzheimer’s years before symptoms appear, offering a non-invasive alternative to blood tests.
Read More
IL-12 Is the Messenger Fueling Alzheimer’s
Microglia can transition from protective to harmful with age, producing inflammatory messengers like IL-12, which accelerates Alzheimer’s.
Read More
Blood Test May Be Means for Early Detection of Dementia
A blood test originally developed for Alzheimer’s can help predict dementia in patients with iRBD years before symptoms appear.
Read More